Modifiedblue cross blue shield - louisianaPolicy AHS - G2011 - Diagnostic Testing of Iron Homeostasis and Metabolism, 1

Diagnostic Testing of Iron Homeostasis & Metabolism

Coverage policy for laboratory testing of iron status (e.g., serum ferritin, transferrin saturation, hepcidin, GlycA) including indications, limitations, and frequency guidance affecting providers ordering these tests for Blue Cross and Blue Shield of Louisiana members.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyDiagnostic Testing of Iron Homeostasis & Metabolism

Policy CodePolicy AHS - G2011 - Diagnostic Testing of Iron Homeostasis and Metabolism, 1

Change TypeMaterial edits: clarified symptomatic requirementadded exclusion for serum hepcidineditorial clarifications

Effective Date06/01/2025

Next Review Date

Key ActionDocument clinical indication in the patient's record to support one of the listed covered indications before ordering iron studies.

SourceLink

POLICY UPDATE CHANGES

Removed '(using serum iron and serum iron binding capacity measurements)' from CC2; CC2 now reads that measurement of serum transferrin saturation MEETS COVERAGE CRITERIA in any of the following.

Edited CC3 to clarify that testing outside of addressed conditions is not allowed, including testing of asymptomatic individuals.

Client requested variance: CC4 added back into policy stating 'Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA.'

06/01/2025 review updated background, guidelines, recommendations, and references but did not change coverage criteria.

Client requested variance removed CC4 previously that stated serum hepcidin testing DOES NOT MEET COVERAGE CRITERIA and removed code 84999.

measurement of serum ferritincovered: ferritin

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

measurement of transferrin saturation

serum hepcidinexcluded test

1-3 moCKD ferritin freq

>1 billionglobal burden

Coverage Criteria for Iron Testing

Serum ferritin - Covered indications

Measurement of serum ferritin MEETS COVERAGE CRITERIA when ANY of the following are met:

Serum ferritin covered indications: a) Evaluation of an individual with abnormal hemoglobin and/or hematocrit levels.

From policy section III item 1a

Serum ferritin covered indications: b) Evaluation and monitoring of iron overload disorders.

From policy section III item 1b

Serum ferritin covered indications: c) Individuals with symptoms of hemochromatosis.

From policy section III item 1c

Serum ferritin covered indications: d) Individuals with first-degree relatives with confirmed hereditary hemochromatosis (see Note 2).

From policy section III item 1d

Serum ferritin covered indications: e) Evaluation of individuals with liver disease.

From policy section III item 1e

Serum ferritin covered indications: f) Evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease.

From policy section III item 1f

Serum ferritin covered indications: g) In males with secondary hypogonadism.

From policy section III item 1g

Serum ferritin covered indications: h) For evaluation and monitoring of patients with chronic kidney disease who are receiving or being considered for treatment for anemia: every 1 to 3 months.every 1 to 3 months

From policy section III items 1h and 1h(i)

Serum ferritin covered indications: i) For individuals on iron therapy: every 1 to 3 months.every 1 to 3 months

From policy section III item 1h(ii)

Transferrin saturation - Covered indications

Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA when ANY of the following are met:

Transferrin saturation covered indications: a) Evaluation of iron overload in individuals with symptoms of hemochromatosis.

From policy section III item 2a

Transferrin saturation covered indications: b) Evaluation of iron overload in individuals with first-degree relatives with confirmed hereditary hemochromatosis (see Note 2).

From policy section III item 2b

Transferrin saturation covered indications: c) Evaluation of iron deficiency anemia.

From policy section III item 2c

Interpretive and diagnostic criteria

Clinical interpretation and diagnostic thresholds described in guidelines and studies:

General ferritin-based diagnosis: Serum ferritin <30 μg/L suggests iron deficiency; interpret results in context of inflammation and consider adjunct tests such as TSAT and CRP when indicated.SF <30 μg/L

Dignass et al.; Garcia-Casal meta-analysis

Inflammatory or chronic disease context: In congestive heart failure (CHF), chronic kidney disease (CKD), or inflammatory bowel disease (IBD) a ferritin <100 μg/L or TSAT <20% can be diagnostic; if ferritin is 100–300 μg/L then TSAT <20% is required to confirm iron deficiency.ferritin <100 μg/L OR (ferritin 100–300 μg/L AND TSAT <20%)

Dignass et al.; ECCO guidance

Iron overload assessment: Ferritin above sex-specific HEIRS thresholds (>200 ng/mL women; >300 ng/mL men) should prompt additional testing for iron overload; therapeutic phlebotomy indicated for SF >1000 ng/mL with high TSAT.

Initial evaluation and diagnostic thresholds

Referenced guideline-based indications and monitoring recommendations for iron studies:

Initial evaluation of anemia: Evaluate patients with anemia for underlying cause and include iron studies: serum iron, total iron binding capacity (TIBC), transferrin saturation (TSAT), and serum ferritin. In inflammatory states consider reticulocyte hemoglobin content and/or hepcidin when available.Ferritin <30 ng/mL and/or TSAT <20% define absolute iron deficiency; ferritin <100 ng/mL may indicate iron deficiency in inflammatory states.

ICCAMS, ECCO, KDIGO

Monitoring frequency

Monitoring recommendations for ferritin and transferrin saturation during specific therapies or disease management:

Monitoring during iron chelation: During iron chelation therapy, check serum ferritin frequently (every 3–6 weeks) to compute running averages and correct for transient variability.every 3–6 weeks

ASH guidelines for quantifying iron overload

Monitoring during ESA therapy and CKD management: For CKD patients receiving ESA therapy, test TSAT and ferritin at least every 3 months and more frequently when initiating or increasing ESA dose, with more frequent monitoring in circumstances where iron stores may become depleted or after IV iron administration.at least every 3 months (more frequently with therapy changes)

KDIGO guideline

Coverage criteria edits and exclusions

Policy edits, clarifications, and explicit exclusions made during recent revisions:

Editorial clarification to CC2: Removed parenthetical wording from CC2; Measurement of serum transferrin saturation now reads as meeting coverage criteria in any of the listed situations without the parenthetical phrase.

Review/Revision History 06/01/2025

Restriction for unlisted situations (CC3): For all other situations not addressed in the coverage criteria, measurement of ferritin or transferrin levels, including transferrin saturation, DOES NOT MEET COVERAGE CRITERIA; testing of asymptomatic individuals is not allowed unless specifically covered.

Edited CC3 to clarify symptomatic requirement; Review/Revision History 06/01/2025

Explicit exclusion (CC4): Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA (client-requested variance reinstated).

Added back by client variance 06/01/2025

Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA. The policy explicitly restates this exclusion added by client variance and clarifies that these assays are not considered covered tests for assessment of iron status. In addition, the use of GlycA testing to measure or monitor transferrin or other glycosylated proteins DOES NOT MEET COVERAGE CRITERIA because GlycA cannot reliably quantify individual glycoprotein concentrations.

Within the portions of the document cited here there are no additional explicit test exclusions beyond those already stated; the evidence and clinical utility sections do not list other tests as excluded in these chunks.

The USPSTF has concluded that current evidence is insufficient (Grade I) to assess the balance of benefits and harms of routine screening for iron deficiency anemia in pregnant individuals to prevent adverse maternal or birth outcomes, and also finds insufficient evidence for routine screening in children ages 6 to 24 months.

For clarity, the policy restates that serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA. This explicit exclusion appears in the indications/limitations section and the revision history.

Measurement of serum ferritin or transferrin (including transferrin saturation) meets coverage criteria only for the specific indications listed in the policy. Measurement of these analytes for situations not explicitly listed in the covered indications is limited by the policy and may not meet coverage criteria.

These referenced chunks do not contain any formal wording that designates tests as 'not medically necessary' beyond the policy statements; therefore no explicit not-medically-necessary determinations are provided in these sections.

If a clinical situation is not addressed by the policy's listed covered indications, measurement of ferritin or transferrin (including transferrin saturation) generally does not meet coverage criteria. Documentation should demonstrate that the requested testing aligns with one of the policy-specified indications and that the individual is symptomatic where required.

Covered Clinical Indications

Evaluation of abnormal hemoglobin/hematocrit, iron overload, hemochromatosis symptoms, first-degree relatives with hereditary hemochromatosis, liver disease, HLH/Still Disease, males with secondary hypogonadism, CKD anemia monitoring, individuals on iron therapy.

Covered clinical scenarios where testing of ferritin and/or transferrin (TSAT) is appropriate:

Evaluation of abnormal hemoglobin/hematocrit: Assessment of an individual with abnormal hemoglobin and/or hematocrit levels (ferritin recommended as part of iron studies).

Policy section III item 1a

Evaluation/monitoring of iron overload: Evaluation and monitoring of iron overload disorders (use ferritin and TSAT as clinically indicated).

Policy section III item 1b

Symptoms of hemochromatosis or family history: Individuals with symptoms of hemochromatosis or first-degree relatives of confirmed hereditary hemochromatosis should be evaluated with ferritin and TSAT as indicated.

Testing Frequency and Monitoring Intervals

inv-59: Serum ferritin monitoring interval (CKD anemia / iron therapy)

Recommended intervalEvery 1 to 3 months for serum ferritin in CKD patients receiving or being considered for anemia treatment and for individuals on iron therapy.

Applicable populationPatients with chronic kidney disease receiving or being considered for anemia treatment; individuals actively on iron therapy.

PurposeEvaluation and monitoring of iron status during anemia management or iron supplementation to guide therapy decisions.

inv-60: Hepcidin follow-up (informational)

Suggested intervalPeriodic follow-up (for example, every six months) of serum hepcidin was suggested in specific disorders (e.g., beta-thalassemia) per the cited study.

Context

Procedure Codes and Thresholds

Listed procedure codesCPT

82728	Ferritin
83540	Iron
83550	Iron binding capacity
84466	Transferrin
0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative (Proprietary test: GlycA; Laboratory Corporation of America)
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma (Proprietary test: Intrinsic Hepcidin IDx™ Test; IntrinsicDx)

inv-17: Serum ferritin diagnostic thresholds

General diagnostic thresholdSerum ferritin <30 μg/L generally indicates iron deficiency.

Inflammatory/CKD/CHF/IBD contextIn CHF, CKD, or IBD, ferritin <100 μg/L or TSAT <20% can be considered diagnostic for iron deficiency.

Intermediate range guidanceIf ferritin is 100–300 μg/L, TSAT <20% is required to confirm iron deficiency.

inv-18: Ferritin thresholds (summary)

Summary of ferritin rulesFerritin <30 μg/L indicates iron deficiency; in inflammatory states or specific populations higher cutoffs apply and sex-specific HEIRS thresholds (>200 ng/mL women, >300 ng/mL men) prompt additional testing for iron overload.

Severe overload trigger

Provider Actions, Documentation, and Billing

Note

No Explicit Authorization/Denial Trigger

No explicit authorization or denial trigger is stated within this policy. Coverage determinations are benefit-dependent and will be made based on the member's benefit coverage at the time of service and any applicable government policies (LCD/NCD) that take precedence.

Coverage determinations depend on member benefits at time of request.
If conflict with government policy (e.g., LCD/NCD), government policy prevails.

Note

No Authorization/Denial Criteria in Policy Text

This policy does not provide standalone authorization or denial criteria beyond the coverage indications listed; instead, it defines covered and not-covered indications/tests and defers operational authorization decisions to benefit rules and government policy.

Policy lists specific covered indications (e.g., abnormal hemoglobin/hematocrit, evaluation of iron overload, symptoms or first‑degree relatives with hereditary hemochromatosis, liver disease, HLH/ Still Disease, CKD monitoring, individuals on iron therapy).
Policy lists specific not-covered tests (e.g., serum hepcidin testing, GlycA).

Definitions and Biomarker Context

Background: Iron homeostasis involves regulated absorption, transport, and storage. Transferrin mediates iron transport, ferritin reflects storage (but is an acute-phase reactant), and the peptide hormone hepcidin controls iron export via ferroportin. Interpretation of ferritin and related biomarkers requires consideration of inflammation, liver disease, and other clinical contexts.

inv-44: Ferritin / Serum ferritin

DefinitionFerritin: intracellular iron storage protein composed of H and L subunits; serum ferritin largely reflects iron stores but is affected by inflammation, liver disease, malignancy, and other conditions.

Serum contextSerum ferritin is primarily composed of L subunits, can be glycosylated, and may rise as an acute phase reactant independent of iron stores.

Clinical implicationElevated serum ferritin may reflect inflammation or liver disease rather than iron overload; interpret with adjunct tests (TSAT, CRP) as needed.

inv-45: Hepcidin

Tests and Uses Not Covered

Not covered: Serum hepcidin testing, including immunoassays, and GlycA testing to measure or monitor transferrin or other glycosylated proteins are not covered. GlycA cannot distinguish contributions from individual glycoproteins, limiting its utility for measuring transferrin concentration.

In the cited reference material there are no additional specific tests explicitly listed as not covered; the document focuses on the evidence base for commonly used iron biomarkers and adjunctive tests rather than enumerating further exclusions.

Advanced or research-focused markers such as non-transferrin-bound iron (NTBI), labile plasma iron (LPI), and specialized imaging (liver iron concentration or cardiac T2*) are described as research tools or not suitable for routine monitoring and therefore are not recommended as standard monitoring tests in this policy context.

The references section does not explicitly list additional test exclusions; it serves to support the clinical discussion and guideline citations rather than to expand the policy exclusion list.

The policy explicitly restates that serum hepcidin testing does not meet coverage criteria, reflected both in the Indications/Limitations section and in the revision history where the client requested that exclusion be re-added.

Measurement of ferritin or transferrin levels for indications not addressed by this policy, including testing of asymptomatic individuals, does not meet coverage criteria and may be denied unless a covered indication and supporting documentation are provided.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyDiagnostic Testing of Iron Homeostasis & Metabolism

Policy CodePolicy AHS - G2011 - Diagnostic Testing of Iron Homeostasis and Metabolism, 1

Change TypeMaterial edits: clarified symptomatic requirementadded exclusion for serum hepcidineditorial clarifications

Effective Date06/01/2025

Next Review Date

Key ActionDocument clinical indication in the patient's record to support one of the listed covered indications before ordering iron studies.

SourceLink

On This Page

SF >200/300 ng/mL; SF >1000 ng/mL for phlebotomy

HEIRS study; Fleming & Ponka

Alternative and adjunct biomarkers: RET-He, hepcidin, GDF-15, and GlycA may be useful in specific contexts (e.g., RET‑He for predicting IV iron responsiveness; hepcidin to help distinguish functional vs absolute deficiency) but assays have limitations and variable performance.study-specific

Auerbach et al.; Abioye et al.; Otvos et al.

Policy section III items 1c and 1d

Liver disease: Evaluation of individuals with liver disease where iron studies may inform diagnosis and management.

Policy section III item 1e

HLH and Still Disease: Evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease where markedly elevated ferritin may be diagnostic or supportive.

Policy section III item 1f

Males with secondary hypogonadism: Assessment of males with secondary hypogonadism where iron overload may contribute to hypogonadism.

Policy section III item 1g

CKD anemia monitoring: Chronic kidney disease patients receiving or being considered for anemia treatment: ferritin testing every 1–3 months to monitor iron status.every 1 to 3 months

Policy section III items 1h and 1h(i)

Individuals on iron therapy: Individuals receiving iron therapy: ferritin testing every 1–3 months to assess response and adjust therapy.every 1 to 3 months

Policy section III item 1h(ii)

Transferrin saturation: evaluation of iron overload with symptoms or family history, and evaluation of iron deficiency anemia.

Clinical indications for measurement of transferrin saturation (TSAT):

TSAT for iron overload evaluation: Evaluation of iron overload in individuals with symptoms of hemochromatosis or with first-degree relatives with confirmed hereditary hemochromatosis.

Policy section III item 2a–2b

TSAT for iron deficiency evaluation: Evaluation of iron deficiency anemia where TSAT complements ferritin to determine iron availability.

Policy section III item 2c; ASH commentary on TSAT utility

Interpretive threshold note: High TSAT values (eg, >85%) are associated with circulating non‑transferrin‑bound iron (NTBI) and increased risk for endocrine and cardiac iron accumulation; interpret TSAT in clinical context and with awareness of limitations during chelation therapy.TSAT >85%

ASH guidelines

Evaluation of suspected iron deficiency or iron overload, monitoring iron status during therapy (including ESA therapy), and assessment in at-risk populations (pregnancy, CKD, CHF, IBD, perioperative anemia management).

Contexts in which ferritin and TSAT testing are supported by evidence and guideline recommendations:

Suspected iron deficiency or overload: Evaluation of suspected iron deficiency or iron overload using ferritin as a primary screening test, interpreted with TSAT and CRP in inflammatory states.SF <30 μg/L; consider adjusted cutoffs in inflammation

Dignass et al.; Garcia-Casal; WHO

Monitoring during therapy: Monitoring iron status during therapy, including ESA therapy and IV iron administration, with ferritin and TSAT used to guide treatment decisions.Per KDIGO: at least every 3 months during stable ESA therapy; more frequent when initiating or changing therapy

KDIGO; ICCAMS

At-risk populations: Assessment in at-risk populations (pregnancy, CKD, CHF, IBD, perioperative patients) with guideline-recommended adjustments to ferritin thresholds and adjunct testing as appropriate.Population-specific cutoffs per WHO and specialty guidelines

WHO; ECCO; ICCAMS

Evaluation of anemia and assessment of iron status (including CKD, surgical patients, IBD, suspected iron deficiency).

Guideline-based recommendations for anemia evaluation and iron-status assessment:

Anemia workup components: Initial evaluation of anemia should include a complete blood count and iron studies (serum iron, TIBC, TSAT, and serum ferritin); in inflammatory states consider reticulocyte hemoglobin content and/or hepcidin when available.Ferritin <30 ng/mL and/or TSAT <20% define absolute iron deficiency; ferritin <100 ng/mL may indicate iron deficiency in inflammatory states.

ICCAMS; KDIGO; ECCO

Use of ferritin in inflammatory states: Because ferritin is an acute phase reactant, higher ferritin cutoffs should be used in inflammatory conditions (eg, ferritin <100 μg/L may indicate iron deficiency in CKD/IBD).ferritin <100 μg/L in inflammatory states

ECCO; Dignass et al.

References supporting evaluation of iron deficiency/overload where ferritin, hepcidin, transferrin receptor, and other biomarkers are used (informational).

References supporting use of ferritin, hepcidin, transferrin receptor, and other biomarkers for evaluation of iron deficiency and overload (informational):

Supporting literature: Multiple evidence-based references are listed supporting the evaluation of iron deficiency, iron overload, and anemia of chronic disease using ferritin, hepcidin, transferrin receptor, RET‑He, and other biomarkers; consult cited literature for assay‑specific performance and context.

Evidence list in policy references

Measurement of serum transferrin saturation meets coverage criteria when one of the policy-specified conditions is present.

Policy coverage stance and application note for transferrin saturation (TSAT):

Coverage rule for TSAT: Measurement of serum transferrin saturation meets coverage criteria when one of the policy‑specified covered conditions is present; testing outside listed indications does not meet coverage criteria.

Policy section III item 2 and CC3 clarifications

Recommendation based on individual study (Ismail et al., 2019) as informational guidance rather than a coverage requirement.

Intended useLongitudinal monitoring of hepcidin to assess iron burden and guide potential future hepcidin-targeted therapies in select disorders.

inv-61: Ferritin and TSAT monitoring intervals

Chelation monitoringEvery 3–6 weeks for serum ferritin monitoring during iron chelation therapy to allow calculation of running averages.

ESA therapy / CKDAt least every 3 months for TSAT and ferritin during ESA therapy or stable CKD management; test more frequently when initiating or changing therapy.

PurposeDetect changes in iron stores during chelation or anemia management and guide dosing/therapy adjustments.

inv-62: Frequency limits (placeholder)

NoteNo explicit frequency limits provided in source chunks for this placeholder block.

ActionRefer to specific test entries or clinical guidelines for applicable monitoring intervals.

ScopePlaceholder — no numeric or interval content available in cited chunks.

inv-63: Frequency limits (placeholder)

NoteNo explicit frequency limits provided in source chunks for this placeholder block.

ActionConsult policy frequency_limits section or primary guidelines for test-specific intervals.

ScopePlaceholder — no numeric or interval content available in cited chunks.

Therapeutic phlebotomy indicated when serum ferritin >1000 ng/mL with high TSAT.

WHO age/inflammation adjustmentsWHO provides age- and inflammation-adjusted ferritin cutoffs for children, adolescents, adults, and pregnant individuals (see WHO guideline for specifics).

inv-19: Ferritin and TSAT thresholds for iron deficiency

Absolute iron deficiencyFerritin <30 ng/mL and/or TSAT <20% define absolute iron deficiency.

Inflammatory statesFerritin <100 ng/mL may define iron deficiency in inflammatory states; consider reticulocyte Hb or hepcidin when available.

Guideline sourceThresholds referenced from ICCAMS, ECCO, and KDIGO/KDOQI guidelines in policy.

inv-20: TSAT risk threshold (NTBI/LPI)

Risk thresholdTransferrin saturation (TSAT) >85% is associated with circulating non-transferrin-bound iron (NTBI) and increased risk for endocrine and cardiac iron accumulation.

Clinical implicationOnce TSAT exceeds ~85%, NTBI/LPI species can appear and contribute to organ iron toxicity; these metrics are primarily research/advanced tools.

Measurement caveatTSAT values cannot be interpreted if iron chelator is present in the bloodstream; withhold chelation before measurement per guidelines.

inv-21: Thresholds (placeholder)

NoteNo numeric thresholds present in the cited chunks for this placeholder block.

ActionRefer to other threshold entries in the policy for numeric guidance.

ScopePlaceholder — no additional numeric data available.

Operational authorization decisions (prior auth) are determined by member benefit at time of service.

Denial Risk

Denial Risk for Testing Outside Allowed Indications

Requests for testing that fall outside the coverage indications described in this policy may be denied. This includes testing asymptomatic individuals or using ferritin/transferrin measurements for indications not listed in the coverage criteria.

Testing outside the conditions addressed in the criteria (including asymptomatic individuals) does not meet coverage criteria and may be denied.
Examples: ferritin or transferrin measurement for indications not listed in CC1–CC2; serum hepcidin testing; GlycA testing.

Documentation Required

Required Clinical Indication and Symptom Documentation

Documentation supporting the medical necessity of ordered iron studies should be present in the medical record. Clinical notes must demonstrate that the indication matches one of the covered situations in this policy and, when applicable, that the individual is symptomatic as required.

Clinical documentation must support one of the listed covered indications (e.g., abnormal hemoglobin/hematocrit, suspected hemochromatosis, evaluation of iron overload, liver disease, HLH/Still Disease, CKD monitoring, individuals on iron therapy).
Documentation should indicate symptom presence when the coverage criterion requires symptomatic individuals (e.g., symptoms of hemochromatosis).

Documentation Required